© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
Oncology
SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer
May 29, 2020
SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.
Nationwide Study Shows Cancer Mortality Benefit Following State Medicaid Expansion
May 29, 2020
The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.
ASCO20 Virtual: Study Assesses COVID-19 Clinical Data, Finds Cancer Mortality Links
May 28, 2020
The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.
ASCO Special Report Offers Guidance on Cancer Care Delivery During Pandemic
May 28, 2020
The American Society of Clinical Oncology (ASCO) recently released a detailed guidance to oncology practices
FDA Approves Olaparib for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer
May 20, 2020
Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.
FDA OKs Atezolizumab for First-Line Treatment of PD-L1 High NSCLC
May 19, 2020
Atezolizumab demonstrated a significant overall survival benefit in individuals with high PD-L1 expression compared with chemotherapy.
Trastuzumab Deruxtecan Granted Breakthrough Designation for HER2-Mutant Metastatic NSCLC
May 19, 2020
Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).
FDA Approves Rucaparib for Some Prostate Cancer Types
May 18, 2020
Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.
Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast Cancer
May 13, 2020
Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
Study Explores Racial Inequalities in Liver Cancer Deaths After Launch of Hepatitis C Treatments
May 12, 2020
"A major clinical and public health priority should be to decrease racial inequalities in mortality following the introduction of lifesavings drugs in the United States and worldwide.”